News | September 14, 2008

European Arc Therapy Pioneer Selects RapidArc to Handle Increasing Patient Workload

September 15 - Ghent University Hospital in Belgium, among the first hospitals in the world to pioneer radiotherapy treatments using arc radiotherapy, is acquiring RapidArc technology from Varian Medical Systems.

The hospital, which has developed its own intensity modulated arc therapy (IMAT) planning system, has carried out such treatments on prostate and gynaecological cancer patients for several years with reportedly impressive results in tumor control and reduced complications. There are now plans to extend such treatments to other sites.

“The problem is that using our own system, it takes half an hour to deliver treatments, even longer if we use image-guided radiotherapy,” said professor Marc van Eijkeren, head of Ghent University Hospital’s department of radiation oncology. “Our normal radiotherapy treatment slots are ten minutes so it means we take up three slots to deliver one arc therapy treatment, placing a big strain on our busy department.

“As more and more patients are becoming eligible for these treatments and patient referrals for arc therapy increase, we knew we needed to find a solution that allowed our patients to have these advanced treatments without causing a backlog. We are convinced that RapidArc is the only commercial system available at the moment that can deliver these treatments in such a short time.”

Professor van Eijkeren says his hospital’s long history with advanced techniques such as IMAT and intensity modulated radiotherapy (IMRT) comes from its goal of gaining greater tumor control and fewer side effects. Ghent University Hospital serves more than 1.5 million people in the northern regions of Belgium. The Clinac iX equipped with Varian’s RapidArc technology is due to be installed at the hospital in October and RapidArc treatments are planned to commence in spring 2009.

For more information: www.varian.com

Related Content

Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
IBA Completes Installation of Two Proteus One Proton Therapy Systems in Japan
News | Proton Therapy | July 30, 2018
IBA (Ion Beam Applications S.A.) announced that they completed the first two installations of the Proteus One proton...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
UZ Leuven Treats First European Patient on Varian Halcyon Cancer Treatment System
News | Intensity Modulated Radiation Therapy (IMRT) | October 25, 2017
Varian recently announced an 80-year-old male with head and neck cancer became the first patient in Europe to be...
Varian Receives FDA 510k Clearance for Halcyon Treatment System
Technology | Intensity Modulated Radiation Therapy (IMRT) | July 05, 2017
Varian Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Halcyon system,...
First New York Metropolitan Hospital Treats Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | July 03, 2017
Accuray Inc. and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS),...
IUCT Oncopole Installs First Radixact Radiotherapy System in France
News | Intensity Modulated Radiation Therapy (IMRT) | June 20, 2017
Accuray Inc. announced that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) in Toulouse, France,...
cervical and endometrial cancer, IMRT, intensity modulated radiation therapy, side effects, ASTRO 2016 study
News | Intensity Modulated Radiation Therapy (IMRT) | September 29, 2016
Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience...